Please login to the form below

Not currently logged in

Fishawack buys JK Associates

Healthcare comms agency adds US-based group to portfolio

The JK brands JK Medical Communications, Arbor Communications, Endpoint Medical Communications and 1010 Digital will work alongside Fishawack's Philadelphia team.

“Along with what is now Fishawack Communications, this is our second US acquisition,” said Oliver Dennis, CEO of the Fishawack Group.

“Clients want integrated agencies that can work together across geographies on global accounts. When we discussed the synergies between us it was obvious – Fishawack needed more depth in the US and JK needed a European-based team with greater resources.”

JK Associates president and CEO John (Zeke) Czekanski and COO Kevin Pawley will continue managing their company's day-to-day operations, and will join the Fishawack board. The two organisations first worked together in 2004, on a joint business pitch.

“Our business model is to have critical mass co-located with our clients with UK-based support for when scale is needed,” said Fishawack group managing director Gail Flockhart.

“This means that in medical communications, the ideal agency profile is one with critical mass in three key locations: the US, the UK, and Switzerland. Fishawack is truly unique in this regard.”

Established 13 years ago, the Fishawack Group of Companies has offices in the UK (near Manchester and Oxford), the US (North Wales and Conshohocken, PA, and Ann Arbor, MI), and Switzerland (Basel and Zofingen).

Fishawack works with pharma, biotechnology and medical device companies, providing services such as medical communications, scientific engagement, market access, clinical and regulatory writing, and pharmacovigilance support.

Article by
Tara Craig

4th April 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?